Condition
Pulmonary Fibrosis Interstitial
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 4 (1)
Trial Status
Unknown1
Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04837131Phase 2Terminated
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
NCT06702228Recruiting
Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland
NCT04818489Phase 4Unknown
Colchicine and Post-COVID-19 Pulmonary Fibrosis
Showing all 3 trials